Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 4 studies | 44% ± 17% | |
GABAergic neuron | 3 studies | 50% ± 6% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 4% | |
interneuron | 3 studies | 40% ± 19% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 30% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 1399.71 | 2641 / 2642 | 100% | 12.86 | 703 / 705 |
adrenal gland | 91% | 236.20 | 235 / 258 | 97% | 6.93 | 223 / 230 |
thymus | 64% | 121.98 | 421 / 653 | 94% | 2.37 | 571 / 605 |
ovary | 19% | 35.31 | 35 / 180 | 95% | 4.48 | 410 / 430 |
kidney | 55% | 104.60 | 49 / 89 | 53% | 1.39 | 480 / 901 |
breast | 13% | 21.90 | 59 / 459 | 91% | 3.39 | 1019 / 1118 |
lymph node | 0% | 0 | 0 / 0 | 100% | 4.30 | 29 / 29 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.13 | 1 / 1 |
intestine | 19% | 37.89 | 186 / 966 | 79% | 2.14 | 417 / 527 |
spleen | 93% | 219.47 | 225 / 241 | 0% | 0 | 0 / 0 |
stomach | 4% | 6.39 | 14 / 359 | 89% | 3.27 | 255 / 286 |
lung | 16% | 27.58 | 94 / 578 | 74% | 2.99 | 859 / 1155 |
skin | 2% | 3.78 | 42 / 1809 | 85% | 3.13 | 399 / 472 |
eye | 0% | 0 | 0 / 0 | 84% | 2.19 | 67 / 80 |
esophagus | 1% | 1.73 | 14 / 1445 | 81% | 4.36 | 148 / 183 |
uterus | 10% | 19.87 | 17 / 170 | 68% | 2.68 | 312 / 459 |
bladder | 0% | 0 | 0 / 21 | 74% | 2.36 | 375 / 504 |
tonsil | 0% | 0 | 0 / 0 | 62% | 1.93 | 28 / 45 |
pancreas | 2% | 2.80 | 6 / 328 | 54% | 1.32 | 97 / 178 |
blood vessel | 53% | 105.01 | 708 / 1335 | 0% | 0 | 0 / 0 |
liver | 1% | 1.19 | 2 / 226 | 28% | 0.67 | 112 / 406 |
prostate | 2% | 3.73 | 5 / 245 | 25% | 0.42 | 123 / 502 |
peripheral blood | 21% | 89.15 | 193 / 929 | 0% | 0 | 0 / 0 |
heart | 7% | 11.65 | 61 / 861 | 0% | 0 | 0 / 0 |
adipose | 6% | 11.52 | 78 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1904294 | Biological process | positive regulation of ERAD pathway |
GO_0016020 | Cellular component | membrane |
GO_0046872 | Molecular function | metal ion binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
Gene name | RNFT2 |
Protein name | Alternative protein RNFT2 Ring finger protein, transmembrane 2 E3 ubiquitin-protein ligase RNFT2 (RING finger and transmembrane domain-containing protein 2) (Transmembrane protein 118) |
Synonyms | TMEM118 |
Description | FUNCTION: E3 ubiquitin-protein ligase that negatively regulates IL3-dependent cellular responses through IL3RA ubiquitination and degradation by the proteasome, having an anti-inflammatory effect. . |
Accessions | ENST00000407967.7 [Q96EX2-5] F8VZS7 Q96EX2 L8EAK7 ENST00000392549.7 [Q96EX2-1] ENST00000677328.1 ENST00000547718.5 ENST00000257575.9 [Q96EX2-1] A0A7I2V5U1 |